Partial Seizures
📧 Sign up to get email alerts when something new happens for Partial Seizures.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-09-29FDA Approved: VIGABATRIN — Original Application (Aurobindo Pharma Limited)
FDA approved an original ANDA for Vigabatrin from Aurobindo Pharma Limited, enabling generic availability of the drug.
-
FDA approval · 2021-05-10FDA Approved: GABAPENTIN — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' generic gabapentin under an Original Application (ANDA 214956); the product is indicated for partial se…
-
CLINICAL_TRIALS trial_result · 2021-04-27Clinical Trial Update: Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy [Phase 2]
Phase 2 trial investigating natalizumab for focal epilepsy has completed with posted results.
-
FDA approval · 2021-03-05FDA Approved: GABAPENTIN — Supplemental Application (Granules Pharmaceuticals Inc)
FDA approved Granules Pharmaceuticals Inc's supplemental application for gabapentin granules, approving a new granulated formulation of a ge…
-
CLINICAL_TRIALS trial_result · 2021-01-25Clinical Trial Update: Pregabalin In Partial Seizures: An Open-Label, International, Multicenter Add-On Therapy Trial. [Phase 4]
An open-label, Phase 4 trial of pregabalin as add-on therapy for partial seizures was completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-01-22Clinical Trial Update: Pregabalin Epilepsy Add-On Trial [Phase 3]
Phase 3 trial update for pregabalin as add-on therapy in partial seizures has completed.
-
FDA approval · 2020-10-20FDA Approved: SABRIL — Supplemental Application (Lundbeck Pharmaceuticals LLC)
The FDA approved a supplemental application for Sabril (vigabatrin) submitted by Lundbeck Pharmaceuticals LLC. The action updates the approv…
-
CLINICAL_TRIALS withdrawal · 2020-09-22Clinical Trial Update: Safety Study of Rufinamide Given as an add-on Therapy to Treat Patients With Seizures [Phase 3]
A Phase 3 safety study of Rufinamide as add-on therapy for refractory partial seizures has been withdrawn.
-
FDA approval · 2020-08-25FDA Approved: OXCARBAZEPINE — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
The FDA approved a supplemental application for oxcarbazepine from Glenmark Pharmaceuticals Inc., USA. This action represents a regulatory u…
-
CLINICAL_TRIALS trial_result · 2020-08-19Clinical Trial Update: Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy [Phase 4]
Phase 4 open-label safety and efficacy study of levetiracetam in epilepsy (partial seizures) completed; results posted.
-
FDA approval · 2020-08-07FDA Approved: GABAPENTIN — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for gabapentin from Sun Pharmaceutical Industries, Inc., granting supplemental approval for this…
-
FDA approval · 2020-04-17FDA Approved: VIGABATRIN — Supplemental Application (Par Health USA, LLC)
The FDA approved a supplemental application for Vigabatrin submitted by Par Health USA, LLC. This action updates the regulatory status for V…
-
CLINICAL_TRIALS trial_result · 2020-02-21Clinical Trial Update: A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures [Phase 3]
A Phase 3 study evaluating the safety and tolerability of pregabalin as add-on therapy in pediatric and adult subjects with partial onset se…
-
CLINICAL_TRIALS trial_result · 2019-06-10Clinical Trial Update: Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label Method [Phase 3]
Phase 3 follow-up open-label study of levetiracetam for partial-onset seizures in epilepsy; results posted after completion.
-
FDA approval · 2019-05-31FDA Approved: SABRIL — Supplemental Application (Lundbeck Pharmaceuticals LLC)
FDA approved a supplemental application for Sabril (vigabatrin) from Lundbeck Pharmaceuticals LLC. The action completes an approved suppleme…
-
FDA approval · 2019-05-31FDA Approved: FELBAMATE — Original Application (Novitium Pharma LLC)
FDA approved an Original Application for felbamate by Novitium Pharma LLC, enabling a generic felbamate product for seizure disorders. The p…
-
CLINICAL_TRIALS trial_result · 2018-08-29Clinical Trial Update: A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs) [Phase 2]
Long-term extension study of E2007 in patients with refractory partial seizures completed; results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-06-06Clinical Trial Update: Once-A-Day Pregabalin For Partial Seizures [Phase 3]
Phase 3 trial update for once-daily pregabalin in partial seizures has completed with results posted.
-
FDA approval · 2018-05-14FDA Approved: GABAPENTIN — Original Application (ACI Healthcare USA, Inc.)
FDA approved an Original Application (ANDA) for Gabapentin by ACI Healthcare USA, Inc., authorizing a generic gabapentin product.
-
FDA approval · 2018-03-13FDA Approved: VIGABATRIN — Original Application (Amneal Pharmaceuticals NY LLC)
FDA approved Amneal's generic version of vigabatrin under an Original Application (ANDA 210155), enabling marketing of the drug for its esta…
-
FDA approval · 2018-03-08FDA Approved: FOSPHENYTOIN SODIUM — Supplemental Application (West-Ward Pharmaceuticals Corp)
FDA approved a supplemental application for fosphenytoin sodium submitted by West-Ward Pharmaceuticals Corp. The action updates labeling for…
-
CLINICAL_TRIALS trial_result · 2017-07-12Clinical Trial Update: Sabril for Complex Partial Seizures in Adult Tolerability Study (TS) Patients [Phase 4]
A Phase 4 tolerability study of vigabatrin (Sabril) for complex partial seizures was terminated; results were posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-05-11Clinical Trial Update: Remegal Different Doses in Patients With Refractory Partial Seizures [Phase 2]
Phase 2 trial evaluating different doses of Remegal in patients with refractory partial seizures has completed.
-
CLINICAL_TRIALS trial_result · 2017-05-11Clinical Trial Update: Remegal Fixed Dose as Adjunctive Therapy in Patients With Partial Seizures [Phase 3]
A Phase 3 trial of Remegal fixed-dose as adjunctive therapy for partial seizures has completed under sponsor Valexfarm.
-
FDA approval · 2017-04-27FDA Approved: VIGABATRIN — Original Application (Par Health USA, LLC)
FDA approves Vigabatrin original Abbreviated New Drug Application for Par Health USA, LLC (generic entry).